학술논문
Cost-effectiveness of pembrolizumab as first-line treatment of locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-based therapy in the United States.
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15277755